07:00 , Jun 3, 2013 |  BC Week In Review  |  Company News

Alethia, International Biotech Center (IBC) Generium deal

Alethia and IBC Generium partnered to co-develop Alethia's AB-16B5, an IgG2 mAb against clusterin (CLU; APOJ) in preclinical testing for cancer. Alethia will receive an upfront cash payment and R&D funding to...
08:00 , Dec 14, 2009 |  BC Week In Review  |  Clinical News

Alethia preclinical data

In a mouse model of metastatic cancer, AB-16B5 plus Taxotere docetaxel increased tumor growth inhibition by 40-60% vs. chemotherapy alone. In a mouse model of breast carcinoma, AB-16B5 reduced metastasis to the lungs by...